Patient Search
 |
 |
|
KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story |
If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story. https://momentum.vicc.org/2022/04/brighter-outlook/ |
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Lymphoma
Lymphoma
Lymphoma
III
Jallouk, Andrew
NCT05605899
VICCCTT2298
A Randomized, Open-Label Phase 3 Study of Amivantamab + FOLFIRI versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BRAF Wild-Type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy
Multiple Cancer Types
Colon,
Rectal
III
Eng, Cathy
NCT06750094
VICC-DTGIT24167
A Phase 3 Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigator's Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
Head/Neck
Head/Neck
Head/Neck
III
Choe, Jennifer
NCT06496178
VICC-DTHAN23576
An Open-Label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given with or without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer
Not Available
III
Not Available
NCT05253651
VICC-DTGIT23052
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
Not Available
III
Biltibo, Eden
NCT06413498
VICC-DTCTT23578
A Phase 3 Randomized Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK4/6 inhibitor Therapy (OPERA-01)
Not Available
III
Abramson, Vandana
NCT06016738
VICC-DTBRE23292
Phase 3 Accelerated BEP Trial: A Randomised Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumours
Germ Cell (Pediatrics)
Germ Cell (Pediatrics)
Germ Cell (Pediatrics)
III
Borinstein, Scott
NCT02582697
COGAGCT1532
A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1Mutations Who Are Ineligible for Intensive Chemotherapy
Leukemia
Leukemia
Leukemia
III
Fedorov, Kateryna
NCT06852222
VICCHEM25012
A Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination with Trastuzumab and Chemotherapy (XELOX) versus Trastuzumab and Chemotherapy (XELOX) with or without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer
Multiple Cancer Types
Esophageal,
Gastric/Gastroesophageal
III
Gibson, Mike
NCT06532006
VICCGI24578
ALTE2131 Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer an NCORP Phase 3 Study
Ovarian
Ovarian
Ovarian
III
Davis, Elizabeth
NCT06513962
COGALTE2131
